PMID- 23580906
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20130415
LR  - 20211021
IS  - 1898-7249 (Print)
IS  - 1898-7249 (Electronic)
IS  - 1898-7249 (Linking)
VI  - 7
IP  - 1
DP  - 2013 Mar 30
TI  - The risk of herpes zoster in the anti-TNF-alpha era: a case report and review of the 
      literature.
PG  - 1-4
LID - 10.3315/jdcr.2013.1126 [doi]
AB  - BACKGROUND: Tumor necrosis factor-alpha (TNF-alpha) inhibitors represent efficacious 
      therapeutic agents in many chronic inflammatory diseases such as psoriasis and 
      rheumatoid arthritis. However they have been connected with increased risk of 
      infection and reactivation of a variety of infectious agents, such as viruses. 
      The reactivation of varicella zoster virus infection causes herpes zoster (HZ), a 
      self-limiting, dermatomally localized, vesicular rash that can be accompanied by 
      postherpetic neuralgia and severe neurological complications. MAIN OBSERVATIONS: 
      Limited information has been published regarding HZ during therapy with TNF-alpha 
      inhibitors especially for the occurrence of HZ during adalimumab treatment. We 
      report the case of a 58-year-old immunocompetent man with a 18-year history of 
      plaque psoriasis who develops ophthalmic HZ during treatment with adalimumab. 
      CONCLUSION: We report this case to enrich the literature and to highlight the 
      increased risk of HZ infections in patient on anti-TNF-alpha therapy (incidence of HZ 
      is about 3-fold increased respect to general population). Clinically, these 
      infections often have atypical presentations that may hamper prompt diagnosis. 
      Therefore, it is very important to identify early signs and symptoms of herpes 
      zoster in patients on biologic therapy in order to start prompt efficient 
      antiviral treatment to prevent the development of severe complications.
FAU - Di Costanzo, Luisa
AU  - Di Costanzo L
AD  - Department of Dermatology - University of Naples Federico II, Naples, Italy.
FAU - Ayala, Fabio
AU  - Ayala F
FAU - Megna, Matteo
AU  - Megna M
FAU - Gaudiello, Francesca
AU  - Gaudiello F
FAU - Patri, Angela
AU  - Patri A
FAU - Balato, Nicola
AU  - Balato N
LA  - eng
PT  - Case Reports
DEP - 20130330
PL  - Poland
TA  - J Dermatol Case Rep
JT  - Journal of dermatological case reports
JID - 101493700
PMC - PMC3622506
OTO - NOTNLM
OT  - adalimumab
OT  - biological therapy
OT  - etanercept
OT  - herpes zoster
OT  - infliximab
OT  - psoriasis
OT  - viral infection
EDAT- 2013/04/13 06:00
MHDA- 2013/04/13 06:01
PMCR- 2013/03/30
CRDT- 2013/04/13 06:00
PHST- 2012/11/05 00:00 [received]
PHST- 2012/11/18 00:00 [accepted]
PHST- 2013/04/13 06:00 [entrez]
PHST- 2013/04/13 06:00 [pubmed]
PHST- 2013/04/13 06:01 [medline]
PHST- 2013/03/30 00:00 [pmc-release]
AID - 10.3315/jdcr.2013.1126 [doi]
PST - epublish
SO  - J Dermatol Case Rep. 2013 Mar 30;7(1):1-4. doi: 10.3315/jdcr.2013.1126. Print 
      2013 Mar 30.